Navigation Links
Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
Date:12/13/2007

Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed

Diffuse Large B-Cell Lymphoma

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"We have now expanded the ofatumumab clinical development program into a fourth disease area," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope ofatumumab will offer a new and effective treatment option for patients suffering from DLBCL."

About the trial

In this open label trial, each patient will receive 8 weekly infusions of ofatumumab. The first infusion will be 300 mg and the 7 subsequent infusions will be 1000 mg of ofatumumab. Disease status will be assessed 4 weeks after the last infusion and then every 3 months for a total of 24 months after treatment start according to the "Revised response criteria for malignant lymphoma." After 24 months, patients will be followed until initiation of alternative DLBCL treatment or month 60. T
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Harbinger Research Initiates Coverage on HearAtLast
9. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... , , WASHINGTON, Sept. 9 ... health care plan, American Life League challenged the nation,s Catholic bishops ... it clear that they prefer this action to compromising with the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) ...
... ... Education Program are Experts in Child Safety , ... Vancouver, BC (PRWEB) September 9, 2009 -- September sees more than 500,000 ... or after school. So how do parents keep their kids safe when they are in ...
... Workforce Prescriptions ("WRX") announced on Tuesday the launch of the Paradigm ... by a private endowment, developed to honor hospitals that have gone ... without resorting to workforce reductions or dramatic top-down mandates. , ... the paradigm shift in understanding required to see that the number ...
... HILL, N.C., Sept. 9 TSI Healthcare, a national leader in ... recognized in Inc. Magazine,s "Annual Report of the 500|5000 ... successful and innovative businesses in America have been recognized on this ... , , Inc. began publishing this ...
... , , DALLAS, Sept. ... new t-shirt design supporting breast cancer research, ... tee will benefit the Dallas County Affiliate of Susan G. Komen ... black and white - features distinctive Katydid Collection designs, pairing bold ...
... , , LEHI, ... change and full of demands, pressure and stress. This perfect storm ... depressed population - fueling an $80 billion industry of sleep aids, ... XanGo , LLC unveils eleviv(TM), a revolutionary new ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Keeping Kids Safe Through Education 2Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3Health News:TSI Healthcare Recognized by Inc. Magazine 2Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 2Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 3Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 4Health News:XanGo Introduces a New Dietary Supplement That Restores Youthful Vigor - Naturally 2Health News:XanGo Introduces a New Dietary Supplement That Restores Youthful Vigor - Naturally 3
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
(Date:12/24/2014)... 2014 ResMed (NYSE: RMD ) today ... Chinese medical device manufacturer BMC Medical Co., Ltd. ... masks listed below infringe ResMed,s patents, and entered an order ... the United States : , ... , Willow nasal pillows mask , iVolve full face ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2 July, 2007 -- Ablynx today announced ... study of its lead,development programme, ALX-0081, an ... targeting von Willebrand Factor (vWF), which can,reduce ... acute coronary,syndrome. , The Phase I study ...
... own blood can,potentially improve the quality of ... by peripheral vascular disease, according,to a study ... /PRNewswire/ -- Beike,Biotechnology Co., Ltd. (<a target="_blank" ... by Dr. Yang Xiaofeng at its,collaborating hospital ...
Cached Medicine Technology:Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease 2Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease 3
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
McPherson angled tying forceps made of titanium tying forceps, angled 45 shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 84 mm....
McPherson straight tying forceps made of titanium, straight shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 87 mm....
Titanium hoskin suture tying forceps, 4.75"....
Medicine Products: